List of Excipients in Branded Drug GUAIFENESIN EXTENDED RELEASE 600 MG

Generic Drugs Containing GUAIFENESIN EXTENDED RELEASE 600 MG

Company	Ingredient	NDC	Excipient
TIME CAP LABORATORIES INC	guaifenesin	49483-723	COPOVIDONE K25-31
TIME CAP LABORATORIES INC	guaifenesin	49483-723	FD&C BLUE NO. 1 ALUMINUM LAKE
TIME CAP LABORATORIES INC	guaifenesin	49483-723	HYPROMELLOSE
TIME CAP LABORATORIES INC	guaifenesin	49483-723	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in GUAIFENESIN EXTENDED RELEASE 600 MG?

# Of NDCs	Excipient
1	CARBOMER HOMOPOLYMER TYPE
1	CARBOMER HOMOPOLYMER TYPE B
2	CELLULOSE, MICROCRYSTALLINE
1	COPOVIDONE K25-31

Guaifenesin Extended-Release 600 mg: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 6, 2026

Guaifenesin extended-release 600 mg is an OTC expectorant product category with low active-ingredient complexity and meaningful formulation differentiation. The commercial opportunity is concentrated in hydrophilic matrix design, tablet robustness, swallowability, packaging, private-label supply, and consumer positioning rather than in new chemical-entity exclusivity. In the United States, guaifenesin is regulated under the OTC monograph framework, reducing dependence on Orange Book-listed patents and Paragraph IV litigation.

What is guaifenesin extended-release 600 mg?

Guaifenesin is an expectorant used to loosen phlegm and thin bronchial secretions. The 600 mg extended-release dose is generally administered every 12 hours in adults and children 12 years and older, subject to product labeling. The dosage form is typically a large, film-coated tablet or caplet that must be swallowed whole rather than crushed or chewed.

Mucinex 600 mg Extended-Release Tablets are the best-known US reference product. The product is marketed by Reckitt under the Mucinex brand. FDA labeling identifies guaifenesin as the active ingredient and lists inactive ingredients that support matrix formation, compression, lubrication, coating, and tablet processing (DailyMed, n.d.).

Attribute	Commercial profile
Active ingredient	Guaifenesin
Strength	600 mg
Release profile	Extended release
Primary indication	Expectorant
US regulatory pathway	OTC monograph
Typical dosing interval	Every 12 hours
Principal dosage form	Film-coated tablet or caplet
Key commercial reference	Mucinex 600 mg Extended-Release Tablets
Primary consumer issue	Large tablet and swallowing difficulty
Main differentiation levers	Release control, tablet size, coating, packaging, price, brand positioning

What excipients are used in guaifenesin extended-release 600 mg tablets?

The reference product uses a conventional solid oral excipient system built around a hydrophilic polymer matrix. Public labeling identifies excipients including hypromellose, microcrystalline cellulose, povidone, sodium starch glycolate, magnesium stearate, colloidal silicon dioxide, and talc, with coating components also used in the finished tablet (DailyMed, n.d.).

The exact quantitative formula and manufacturing parameters are proprietary. The functional strategy is clear:

Excipient or excipient class	Primary function	Commercial formulation relevance
Hypromellose	Hydrophilic release-control matrix	Controls water penetration, gel formation, and guaifenesin diffusion
Microcrystalline cellulose	Filler and dry binder	Improves compactibility and tablet strength
Povidone	Binder	Supports granule or powder cohesion
Sodium starch glycolate	Superdisintegrant	Promotes tablet breakup and matrix erosion
Magnesium stearate	Lubricant	Reduces ejection force and tooling adhesion
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder flow and content uniformity
Talc	Processing aid and coating component	Supports coating performance and reduces tack
Film-coating polymers	Appearance, handling, taste, and moisture protection	Supports swallowability and brand differentiation

The central technical challenge is balancing prolonged release with adequate matrix erosion. Excessive hypromellose or high-viscosity polymer can delay drug release beyond the intended 12-hour profile. Excessive disintegrant can create dose dumping or an overly rapid initial release. Lubricant concentration and blending time also matter because over-lubrication can reduce tablet hardness and alter dissolution.

How should an excipient strategy be designed for 600 mg guaifenesin extended release?

A commercial formulation should prioritize a robust hydrophilic matrix rather than a highly complex delivery system. Guaifenesin is a high-dose active ingredient, so the excipient burden directly affects tablet dimensions, swallowability, and manufacturing cost.

Matrix-forming strategy

Hypromellose is the most practical primary release-controlling polymer for a 12-hour guaifenesin tablet. Formulators can adjust:

• Polymer viscosity grade
• Polymer concentration
• Particle size
• Direct-compression versus wet-granulation process
• Tablet hardness and porosity
• Coating weight
• Use of secondary matrix polymers

A lower-viscosity hypromellose grade may improve release consistency and tablet manufacturability. A higher-viscosity grade can strengthen release control but may increase tablet size or create dissolution variability.

Compression strategy

Microcrystalline cellulose and povidone provide a practical balance between tablet strength and processability. The formulation should be evaluated for:

• Tensile strength
• Friability
• Capping and lamination
• Ejection force
• Weight variation
• Content uniformity
• Scale-up sensitivity

The high active load makes direct compression attractive from a cost perspective, but wet granulation may improve flow and content uniformity where the active or excipient blend has poor compactibility.

Disintegration and release control

Sodium starch glycolate can support matrix erosion and prevent an excessively persistent tablet core. Its level should be optimized against the hypromellose concentration. The target is controlled erosion rather than immediate tablet disintegration.

Dissolution testing should examine the full intended dosing interval and include agitation conditions that can identify alcohol-induced release acceleration, mechanical disruption, and food effects. The product should also be evaluated after crushing or chewing to confirm that the labeling prohibition is technically justified.

What formulations are protected by guaifenesin extended-release patents?

The current commercial value of guaifenesin extended-release 600 mg is unlikely to depend on an active-ingredient patent. Guaifenesin is an established compound, and the US product category is regulated as an OTC monograph drug rather than as a new prescription product.

Historical protection may have covered sustained-release compositions, matrix systems, tablet architectures, manufacturing methods, or specific excipient ratios. Those rights must be assessed by jurisdiction and claim scope. A formulation patent can expire while the commercial product continues to benefit from brand recognition, trade dress, manufacturing know-how, and retailer placement.

IP category	Relevance to a 600 mg product
Compound patent	No meaningful commercial barrier expected for established guaifenesin
Orange Book patent	Generally not the principal US exclusivity mechanism for OTC monograph products
Formulation patent	Potential historical protection for release profile or matrix composition
Method-of-use patent	Limited value where the expectorant use is established and monograph-covered
Manufacturing know-how	Can remain commercially relevant despite patent expiry
Trademark and trade dress	Important for Mucinex and competing branded products
Packaging and child-resistance design	Potentially protectable, but rarely a complete market barrier

When does guaifenesin 600 mg lose exclusivity?

Guaifenesin 600 mg does not have a single conventional prescription-drug exclusivity date. US market access is governed primarily by the OTC monograph framework in 21 C.F.R. § 341, which establishes conditions for marketing expectorant products containing guaifenesin.

The practical consequence is that a compliant competitor can enter without waiting for expiration of a branded NDA exclusivity period. A competitor must still meet applicable requirements for active ingredient, dosage form, labeling, manufacturing quality, stability, and product registration or listing.

Exclusivity timeline

Milestone	Commercial significance
Guaifenesin established as an OTC expectorant	Active ingredient becomes available for monograph-based competition
Mucinex 600 mg launch	Creates brand and formulation reference product
Historical formulation patents	May restrict specific compositions during their term
Patent expiration	Removes the relevant patent barrier but does not remove manufacturing or quality requirements
OTC monograph competition	Enables compliant private-label and branded alternatives
Current market	Competition focuses on price, retail distribution, dosage form, and consumer attributes

What is the Orange Book status of guaifenesin extended-release 600 mg?

The Orange Book is not the principal regulatory listing for standard OTC monograph guaifenesin products. Orange Book patent and exclusivity analysis is primarily relevant to approved prescription and certain OTC NDA products. A monograph-compliant guaifenesin extended-release product generally does not rely on an Orange Book-listed patent to prevent competing entry.

This structure also reduces the relevance of Paragraph IV certifications. A conventional monograph product does not enter through the same ANDA patent-certification process used for a prescription product referencing an approved NDA.

Are there Paragraph IV challenges or biosimilar risks?

No conventional biosimilar risk exists because guaifenesin is a small-molecule active ingredient, not a biologic. Paragraph IV litigation is also not the normal competitive pathway for a monograph-compliant guaifenesin product.

Competitive disputes are more likely to involve:

• Product labeling
• Monograph compliance
• Trademark infringement
• False advertising
• Trade dress
• Product quality
• Manufacturing deviations
• Comparative claims about release duration or symptom relief

A company that pursues a new proprietary formulation outside the monograph may create a different regulatory and patent profile. That strategy could support NDA-based protection, but it would also increase development cost and regulatory burden.

What commercial opportunities exist for guaifenesin extended-release 600 mg?

The strongest opportunities are in differentiated OTC products and contract manufacturing.

Private-label and retailer products

Retailers can offer lower-priced 600 mg extended-release guaifenesin under store brands. The formula can remain technically conventional while competing through:

• Lower retail price
• Multipack sizes
• Seasonal promotions
• Retailer-exclusive packaging
• Pharmacy and club-store distribution
• E-commerce assortment

Because the active ingredient is established and the dosage form is familiar, market entry risk is lower than for a novel OTC delivery system.

Swallowability and tablet-size reduction

A 600 mg dose creates a physical tablet-size constraint. A smaller caplet, smoother film coating, or alternative tablet geometry can address a major consumer complaint. Reducing size without compromising the release profile may require higher-density excipients, more efficient granulation, or a multiparticulate system.

Potential product concepts include:

• Smaller film-coated caplets
• Bilayer tablets
• Mini-tablet capsules
• Sprinkleable multiparticulates, subject to labeling and release validation
• Dye-free and low-allergen versions
• Easy-open senior-friendly packaging

Formulation simplification

A simplified excipient system can reduce cost and supply-chain risk. Opportunities include replacing multiple processing aids with multifunctional excipients, reducing colorants, and qualifying dual-source grades of hypromellose, microcrystalline cellulose, and lubricants.

The commercial benefit depends on maintaining dissolution equivalence, tablet robustness, stability, and acceptable appearance.

Combination products

Guaifenesin is often combined in OTC products with dextromethorphan, acetaminophen, pseudoephedrine, or phenylephrine. A 600 mg extended-release guaifenesin component could support combination products, but the regulatory and safety burden is higher. Combination products require careful assessment of dosing intervals, contraindications, abuse potential, cardiovascular warnings, and label space.

A standalone guaifenesin product has a simpler risk profile and can target consumers who do not want a multi-symptom medicine.

What manufacturing and IP barriers exist?

The principal barriers are operational rather than fundamental patent barriers.

Manufacturing barriers

Key risks include:

• High-dose tablet weight
• Poor powder flow
• Segregation during high-speed compression
• Variable matrix hydration
• Dissolution drift across scale
• Tablet capping and lamination
• Coating defects
• Moisture sensitivity
• Inconsistent release after prolonged storage

A robust process should control granule or blend particle-size distribution, compression force, lubricant blending, tablet hardness, coating weight, and dissolution performance.

Intellectual-property barriers

A competitor should screen claims covering:

• Hydrophilic matrix formulations
• Specific hypromellose grades or concentration ranges
• Bilayer or multilayer tablets
• Extended-release guaifenesin combinations
• Multiparticulate delivery systems
• Manufacturing processes
• Packaging and device features
• Trademarks and trade dress

The absence of an Orange Book patent does not eliminate risk from non-Orange-Book formulation patents, trademarks, or unfair-competition claims.

How strong is the patent estate for guaifenesin extended-release 600 mg?

The patent estate is best characterized as weak for blocking ordinary monograph-based entry and potentially stronger for narrow formulation implementations. A conventional hypromellose-matrix tablet using standard excipients is unlikely to provide durable exclusivity by itself unless supported by a narrowly drafted and still-enforceable patent claim.

Estate component	Relative strength
Guaifenesin molecule	Low
Standard 600 mg extended-release tablet	Low to moderate
Specific release profile	Moderate if claim scope is defensible
Novel multiparticulate system	Moderate to high, depending on claims
Manufacturing process	Moderate
Brand and trade dress	High commercial relevance for established products
OTC monograph status	Enables entry rather than exclusivity

What generic launch scenarios exist?

Three launch models are commercially realistic.

1. A direct private-label equivalent using a conventional extended-release matrix and monograph-compliant labeling.
2. A branded value product differentiated by tablet size, coating, packaging, or consumer claims.
3. A proprietary delivery system using mini-tablets, multiparticulates, or a reduced-size dosage form.

The first model has the lowest development cost and the greatest price pressure. The third model has more differentiation potential but requires stronger technical evidence and may create additional patent and regulatory exposure.

Key Takeaways

• Guaifenesin extended-release 600 mg is a mature OTC monograph opportunity, not a conventional prescription exclusivity opportunity.
• The core excipient strategy uses hypromellose for release control, microcrystalline cellulose and povidone for compression, sodium starch glycolate for matrix erosion, and standard processing aids.
• Tablet size, swallowability, dissolution robustness, and cost are the main formulation priorities.
• Orange Book patents, Paragraph IV litigation, and biosimilar competition are generally not central to the standard US product category.
• The strongest commercial opportunities are private-label supply, smaller tablets, dye-free products, simplified excipient systems, and differentiated packaging.
• Patent value is more likely to arise from specific delivery systems or manufacturing processes than from guaifenesin itself.
• Brand recognition, retail distribution, and trade dress remain important competitive assets for Mucinex and other established products.
• Revenue exposure for the 600 mg SKU is not separately disclosed by Reckitt, so product-level sales cannot be reliably quantified from public company reporting.

FAQs

Can guaifenesin extended-release 600 mg be formulated as a smaller tablet?

Yes. Size reduction may be achieved through higher-density excipients, optimized granulation, increased drug loading, or multiparticulate technology. The release profile, tablet strength, stability, and swallowability must remain acceptable.

Is hypromellose mandatory for guaifenesin extended release?

No. Hypromellose is a practical and widely used matrix polymer, but other hydrophilic polymers or coated multiparticulate systems may be evaluated. Any substitute must provide reproducible 12-hour release and acceptable manufacturing performance.

Can a company market guaifenesin 600 mg extended release without an NDA?

A product that meets applicable OTC monograph conditions may generally be marketed through the monograph framework rather than through an NDA. Products that depart materially from monograph conditions may require a different FDA pathway.

What is the main consumer weakness of 600 mg guaifenesin tablets?

The main weakness is tablet size and swallowing difficulty. Coating smoothness, tablet geometry, and alternative dosage forms can improve user acceptance without changing the active ingredient.

Are guaifenesin extended-release formulations suitable for global commercialization?

Potentially, but regulatory classification, permitted claims, dose intervals, excipient standards, labeling, and patent rights vary by country. A formulation may qualify as an OTC medicine in one market and require a different authorization pathway in another.

References

1. Code of Federal Regulations. (2024). 21 C.F.R. § 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. U.S. Government Publishing Office.

2. DailyMed. (n.d.). Mucinex extended-release tablets, guaifenesin 600 mg: Product labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2020). Coronavirus Aid, Relief, and Economic Security Act section 505G: Over-the-counter monograph drugs. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files/approved-drug-products-therapeutic-equivalence-evaluations-orange-book